Comparison of Efficacy and Tolerability of Fulvestrant+Placebo vs Fulvestrant+Palbociclib as First Line Therapy for Postmenopausal Women With HR+ Metastatic BC Treated With 5 Years of Hormonal Therapy Remaining Disease Free More Than 12 Months After Completion or Have de Novo Metastatic Disease

Condition:   Breast NeoplasmsInterventions:   Drug: PD-0332991 (Palbociclib);   Drug: Fulvestrant;   Drug: PlaceboSponsors:   Spanish Breast Cancer Research Group;   AstraZenecaNot yet recruiting - verified February 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

We report a unique case of a 60-year-old woman developing endometrial cancer in a uterine deposit 18 years after she had undergone laparoscopic subtotal hysterectomy with morcellation for benign pathology. She had used unopposed estrogen as menopausal hormone therapy. She presented with a pelvic mass that was causing pressure symptoms. On imaging, the mass had an enhancing vascular nodular component and appeared to abut normal ovaries and the residual cervix. She proceeded to laparotomy, where a 12 cm pelvic mass was found morbidly adherent to the bladder anteriorly and to the cervical stump. The pelvic mass was excise...
Source: Case Reports in Womens Health - Category: OBGYN Source Type: research
Sleep disturbances such as insomnia are extremely common, especially in women after menopause. According to data from the National Institutes of Health, sleep disturbance varies from 16% to 42% before menopause, from 39% to 47% during perimenopause, and from 35% to 60% after menopause. Insomnia is a serious medical problem defined by frequent difficulty falling or staying asleep that impacts a person’s life in a negative way. Hormone changes around menopause can lead to sleep problems for many reasons, including changing sleep requirements, increased irritability, and hot flashes. What menopausal women eat could have...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Fatigue Food as medicine Healthy Eating Menopause Nutrition Sleep Source Type: blogs
DNA changes in a common type of breast cancer cell may be linked to hormone therapy resistance, according to a study published inNature Communications.Science Daily
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
To identify variables that predict persistent hypogonadism and castration in patients with prostate cancer (PCa) treated with brachytherapy (BT).
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
ConclusionIn the neoadjuvant setting, the pCR rate with the standard TCbHP  →  T-DM1+P regimen was numerically better than the TCbHP regimen alone and significantly better in patients with ER+. Personalization of the T-DM1+P regimen could serve as a reasonable approach to minimize toxicity while maintaining efficacy.Trial registration ID: UMIN-CTR: UMIN000014649.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsDisease progression occurred intracranially more often than extracranially following resection of a solitary BCBM. In ER+ patients, postoperative hormonal therapy was associated with longer OS. Postoperative HER2-targeted therapy did not show survival benefit in HER2+ patients. These results should be validated in larger cohorts.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ABSTRACT Introduction: Tables predicting the probability of a positive bone scan in men with non-metastatic, castrate-resistant prostate cancer have recently been reported. We performed an external validation study of these bone scan positivity tables. Materials and Methods: We performed a retrospective cohort study of patients seen at a tertiary care medical center (1996-2012) to select patients with non-metastatic, castrate-resistant prostate cancer. Abstracted data included demographic, anthropometric, and disease-specific data such as patient race, BMI, PSA kinetics, and primary treatment. Primary outcome was metastasi...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
AbstractPurposeGiven that 27-hydroxycholesterol (27HC) is the first identified endogenous selective estrogen receptor modulator, the aim of this study was to investigate the extent to which dietary or lifestyle factors impact circulating 27HC concentrations in a large-scale setting.MethodsThis cross-sectional analysis included 1,036 women aged 35 –65 years who served as controls in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heidelberg breast cancer case–control study. Circulating 27HC was quantified in serum using liquid chromatography/tandem mass spectrometry. Generalized line...
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Hormone therapy is an effective and non-toxic therapy for oestrogen and progesterone receptor-positive breast cancer and for prostate cancer. Serum concentrations of oestradiol and testosterone are controlled by the hypothalamic-pituitary-gonadal pathway. Oestradiol is produced in premenopausal women from the ovaries, and in postmenopausal women by peripheral conversion of adrenal androgens by aromatase. In premenopausal women with breast cancer and men with prostate cancer, treatment is primarily achieved by castration.
Source: Medicine - Category: Internal Medicine Authors: Tags: Systemic therapy Source Type: research
CONCLUSIONS: Compared to women with no history of thyroid disorder, hypothyroidism was associated with a lower risk of breast cancer. This was mainly seen among those who received thyroid replacement therapy and had never used menopausal hormone therapy. Among the treatment options for hypothyroidism, levothyroxine had the strongest inverse association with breast cancer risk. PMID: 31918623 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
More News: Cancer & Oncology | Hormonal Therapy | Hormones | Research | Women